If you found the word “fraboc” in an old referral letter, a clinic document, or a family history questionnaire, you’re not imagining things and you’re not missing some obvious piece of medical knowledge. It’s a retired tool, and the confusion is completely reasonable.
Quick answer
FRABOC (usually written FRA-BOC) stands for Familial Risk Assessment – Breast and Ovarian Cancer. It was an online tool built for Australian health professionals, not patients, to estimate someone’s inherited risk of breast or ovarian cancer based on family history. Cancer Australia ran it for years and then took it down. It’s been replaced by iPrevent, along with a handful of other risk calculators that are still active.
What FRABOC actually was
FRA-BOC lived on the Cancer Australia website and worked the way most family history calculators do. A clinician, usually a GP or practice nurse, entered details about a patient’s relatives: who had breast or ovarian cancer, how old they were at diagnosis, how closely related they were, and whether the cancer was on the mother’s or father’s side. The tool ran that information against known patterns of hereditary risk and spit out a category. Average risk, moderately increased risk, or potentially high risk.
That category mattered because it changed what happened next. Someone flagged as average risk kept going with routine screening on the standard schedule. Someone flagged as potentially high risk usually got referred for genetic counselling, and possibly genetic testing for mutations like BRCA1 or BRCA2, plus a different, more intensive screening plan.
It’s worth saying plainly: FRA-BOC was never meant for someone to plug in their own family tree at home and get a diagnosis. It was a clinical decision-support tool, built to standardize how GPs sorted patients before a specialist referral.
Why it’s gone
Cancer Australia retired FRA-BOC as risk assessment models improved. The newer generation of tools does more than count affected relatives. Some incorporate breast density, reproductive history, and hormone exposure alongside family history, which gives a more complete picture of an individual’s actual risk rather than a rough family pattern. iPrevent is the tool Cancer Australia points to now, and it’s designed for the same audience: doctors and nurses working through a risk conversation with a patient, not the general public typing symptoms into a search bar.
This one is worth naming directly for readers outside Australia: FRA-BOC and its replacement, iPrevent, are built around the Australian healthcare system and its specific screening pathways. If you’re in the US, the family history conversation still happens, but it usually runs through a different set of tools. The transition to iPrevent shows just how much breast cancer risk assessment has evolved. Instead of relying mainly on family history, the newer tool takes a broader view, considering factors such as breast density, reproductive history, hormone use, and other individual characteristics. It also provides estimated five-year and lifetime risk levels, giving women a more detailed picture of their personal risk.
That represents a more complete approach to risk assessment because breast cancer risk is influenced by more than one factor.
Still, the central message behind FRA-BOC remains important. A family history of breast cancer is meaningful information and should be taken seriously and interpreted in the right context. Women deserve clear, personalized information about their risk rather than being left to wonder about it on their own.
What US patients and providers use instead
In the United States, family history-based breast and ovarian cancer risk is typically assessed with one or more of these:
- Tyrer-Cuzick (IBIS) model: factors in family history, hormonal and reproductive history, and breast density
- Gail model: widely used in primary care, though it weighs family history less heavily than the others
- BRCAPRO or BOADICEA: statistical models that estimate the probability of carrying a BRCA1 or BRCA2 mutation, often used before deciding whether genetic testing makes sense
- NCCN genetic testing criteria: the guidelines most US providers use to decide who should be referred for genetic counselling in the first place
None of these are something you run on your own and treat as a final answer. They’re starting points for a conversation with your provider, the same role FRA-BOC used to play in Australia.
Comparison: FRA-BOC vs. current risk tools
| Tool | Status | Region | Who uses it | What it factors in |
|---|---|---|---|---|
| FRA-BOC | Retired | Australia | Was: GPs, nurses | Family history pattern only |
| iPrevent | Active | Australia | Health professionals + patients | Family history, breast density, hormonal factors |
| Tyrer-Cuzick (IBIS) | Active | US and international | Health professionals | Family history, breast density, reproductive history |
| Gail model | Active | US | Primary care providers | Personal and limited family history factors |
| BOADICEA / BRCAPRO | Active | US and international | Genetic counselors, specialists | Detailed family pedigree, mutation probability |
If your family history worries you
A rough rule of thumb: if you have one or more first-degree relatives (parent, sibling, child) diagnosed with breast cancer before 50, ovarian cancer at any age, or multiple relatives on the same side of the family with either cancer, that’s usually enough to bring up genetic counseling with your provider. Male breast cancer anywhere in the family, or a known BRCA mutation in a relative, are also reasons to ask sooner rather than later.
You don’t need to have all the details memorized before that appointment. Write down what you know, including approximate ages at diagnosis, and let your provider or a genetic counselor build the fuller picture from there.
FAQs
Is FRABOC a genetic test?
No. It was a family history questionnaire that produced a risk category, not a lab test. Actual genetic testing, like BRCA1/BRCA2 testing, is a separate step that a genetic counselor typically orders after a risk assessment suggests it’s worth doing.
Can I still access FRA-BOC somewhere online?
Cancer Australia has taken it down. If you find a working link elsewhere, treat it as outdated and don’t rely on the output for current medical decisions.
Why does an old document I have still mention it?
Clinic templates and referral letters get updated slowly. FRA-BOC was in wide use for years, so it’s still floating around in older paperwork and PDFs even though the live tool is gone.
Is iPrevent the direct US equivalent?
Not exactly. iPrevent is built around Australian screening guidelines. US patients and providers generally use Tyrer-Cuzick, the Gail model, or NCCN criteria instead, even though the underlying goal, identifying who needs closer monitoring or genetic counseling, is the same.
Does a moderate risk result mean I’ll get cancer?
No. A risk category estimates probability across a population, not a prediction for one person. It’s a tool for deciding how closely to monitor, not a forecast.
Bottom line
FRABOC was a real tool, just not one that’s still running. It stood for Familial Risk Assessment – Breast and Ovarian Cancer, it lived on Cancer Australia’s site, and it’s since been replaced by iPrevent in Australia. If you’re piecing together your own risk picture from family history, the tool name matters less than the conversation. Bring your family history to your provider, ask directly whether genetic counseling makes sense for your situation, and let them point you to whichever current model applies where you live.
Dr. Tania Adib is a Board Certified OB/GYN based in the northern suburbs of Chicago. She earned her undergraduate degree from the University of Notre Dame and her medical degree from Georgetown University in Washington, D.C., before completing her residency in Obstetrics and Gynecology at Magee-Womens Hospital, University of Pittsburgh Medical Center. Her clinical interests include full-spectrum obstetrics and gynecology, from the first period through the menopausal years, contraception, and abnormal bleeding.